Seres Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of live biotherapeutic products that utilize carefully selected consortia of live bacteria to modulate the human microbiome. The company focuses on innovative treatments for a range of serious diseases by targeting the composition and function of the gut microbiota, particularly the colonic microbiome. Seres has a robust pipeline supported by rigorous scientific research and a team experienced in drug development and microbiome science. Notably, the company pioneered the FDA approval of the first oral live biotherapeutic, emphasizing its leadership in this emerging field. Seres Therapeutics plays a significant role in advancing microbiome therapeutics, aiming to transform patient care through novel microbial interventions.